Literature DB >> 16296748

Bioadhesive properties of pegylated nanoparticles.

Krassimira Yoncheva1, Sara Gómez, Miguel Angel Campanero, Carlos Gamazo, Juan M Irache.   

Abstract

The design of bioadhesive nanoparticles (NPs) for targeting specific sites within the gut remains a major challenge. One possible strategy to solve this problem may be the use of pegylated NPs. In general, these carriers display different bioadhesive properties to nondecorated NPs. Thus, pegylated NPs show a higher ability to interact with the small intestine mucosa rather than with the stomach. However, the type of surface conformation of polyethylene glycol chains appears to have a great influence on the behaviour of these NPs. Theoretically, the traditional 'brush' polyethylene glycol corona would facilitate the penetration of the pegylated particles through the mucus layer and the subsequent adhesive interaction with the mucosa, which would promote their absorption by intestinal enterocytes. On the contrary, pegylated NPs with a 'loop' conformation would increase the time of residence of the adhered fraction of particles in the mucosa.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16296748     DOI: 10.1517/17425247.2.2.205

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  15 in total

1.  In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.

Authors:  Savita Bisht; Georg Feldmann; Jan-Bart M Koorstra; Michael Mullendore; Hector Alvarez; Collins Karikari; Michelle A Rudek; Carlton K Lee; Amarnath Maitra; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

2.  Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier.

Authors:  Ying-Ying Wang; Samuel K Lai; Jung Soo Suk; Amanda Pace; Richard Cone; Justin Hanes
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

3.  Influence of polymeric carrier on the disposition and retention of 20(R)-ginsenoside-rg3-loaded swellable microparticles in the lung.

Authors:  Xiuhua Wang; Xiao Zhang; Linlin Fan; Huan He; Xiaofei Zhang; Yuyang Zhang; Shirui Mao
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

Review 4.  PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.

Authors:  Zahid Hussain; Shahzeb Khan; Muhammad Imran; Muhammad Sohail; Syed Wadood Ali Shah; Marcel de Matas
Journal:  Drug Deliv Transl Res       Date:  2019-06       Impact factor: 4.617

5.  Novel mucoadhesive system based on sulfhydryl-acrylate interactions.

Authors:  Maya Davidovich-Pinhas; Havazelet Bianco-Peled
Journal:  J Mater Sci Mater Med       Date:  2010-04-09       Impact factor: 3.896

6.  Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse.

Authors:  Katharina Maisel; Laura Ensign; Mihika Reddy; Richard Cone; Justin Hanes
Journal:  J Control Release       Date:  2014-11-04       Impact factor: 9.776

Review 7.  The importance of the vaginal delivery route for antiretrovirals in HIV prevention.

Authors:  Lindsay M Ferguson; Lisa Cencia Rohan
Journal:  Ther Deliv       Date:  2011-12

Review 8.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.

Authors:  Samuel K Lai; Ying-Ying Wang; Justin Hanes
Journal:  Adv Drug Deliv Rev       Date:  2008-12-13       Impact factor: 15.470

Review 9.  Nanoparticulate adjuvants and delivery systems for allergen immunotherapy.

Authors:  Juliana De Souza Rebouças; Irene Esparza; Marta Ferrer; María Luisa Sanz; Juan Manuel Irache; Carlos Gamazo
Journal:  J Biomed Biotechnol       Date:  2012-02-26

10.  Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.

Authors:  Claire Vanpouille-Box; François Hindré
Journal:  Front Oncol       Date:  2012-10-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.